Krystal Biotech, Inc.

NASDAQ:KRYS

Biotechnology

Healthcare
$315.34 +5.66%

+$18.29 today

Market cap
$9.34B
Beta
0.53
P/E (TTM)
44.5
EPS (TTM)
$7.68
52W Low $130.17High $347.67

Volume 0.35M

Average 0.29M

KRYS Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Krystal Biotech, Inc.NASDAQ: KRYS

Net Margin · Q2 FY2026 · quarter ended Jun 2026

Net margin widens to 45.9%

Net margin was 45.9% in Q2 FY2026, up 6.0 pp from a year earlier. On a trailing-twelve-month basis it was 54.8%, up 14.0 pp year over year.

Context

  • Net margin widened in 2 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 6 analysts of 46.8% for the fiscal year ending Dec 2026, down from 52.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
45.9%-2.1 pp QoQ
Last fiscal yearDec 2025
52.6%+21.9 pp YoY
LTMJun 2026
54.8%+14.0 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+6.0 pp-37.3 pp-43.3 pp
1 year+21.9 pp-5.8 pp-27.8 pp
3 years—-4.5 pp—
5 years-3.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
52.6%
Year-over-year change
+21.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How KRYS compares with its peers on the latest reported figures

  • KRYS's LTM Jun 2026 net margin of 54.8% is the 2nd highest of the 4 companies compared; the peer median is -151.1%.
  • Its year-over-year change of +14.0 pp is the 2nd highest of 3, against a peer median of +52.1 pp.
KRYS Competitors Peer median
Net Margin for KRYS and competitors
Company Period LTM level YoY 3-year change
ABEOAbeona Therapeutics Inc.LTM Mar 2026454.9% —+4030.4 pp
KRYSKrystal Biotech, Inc.LTM Jun 202654.8% +14.0 pp—
MGTXMeiraGTx Holdings plcLTM Mar 2026-151.1% +333.8 pp+673.9 pp
RGNXREGENXBIO Inc.LTM Mar 2026-330.2% -229.6 pp+134.9 pp
SANASana Biotechnology, Inc.FY2025— ——
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding KRYS) -151.1%+52.1 pp+673.9 pp

Competitors are the stored peer set for KRYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0050.7M290.52M389.13M
Cost of Revenue003.09M20.06M28.77M
Gross Profit0047.61M270.45M360.36M
Gross Margin——93.9%93.1%92.6%
Research & Development27.88M42.46M46.43M53.57M58.05M
Selling, General & Admin40.39M77.74M98.4M113.69M146.74M
Operating Expenses68.28M145.2M157.33M204.76M199.06M
Depreciation & Amortization2.77M4.05M5.01M6.71M6.55M
EBITDA(65.31M)(116.14M)(92.22M)109.91M196.02M
EBITDA Margin——-181.9%37.8%50.4%
Operating Income(68.28M)(145.2M)(109.73M)65.7M161.3M
Operating Margin——-216.4%22.6%41.5%
Interest Income197K5.22M22.62M29.66M28.18M
Interest Expense1.49M0000
Other Income / Expenses(1.3M)5.22M122.62M29.66M28.18M
Income Before Tax(69.57M)(139.98M)12.9M95.36M189.47M
Pre-Tax Margin——25.4%32.8%48.7%
Income Tax Expense001.97M6.2M(15.36M)
Net Income(69.57M)(139.98M)10.93M89.16M204.83M
Net Margin——21.6%30.7%52.6%
EPS (Basic)(3.13)(5.49)0.403.127.08
EPS (Diluted)(3.13)(5.49)0.393.006.84
Weighted Avg Shares22.2M25.49M27.15M28.59M28.94M
Weighted Avg Shares (Diluted)22.2M25.49M27.75M29.74M29.95M

Krystal Biotech, Inc.

NASDAQ:KRYS

Intrinsic Alpha fair value

Locked

Current Price

$315.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.